Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD
Posted inDiabetes & Endocrinology Gastroenterology news

Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD

This prospective cohort study compares semaglutide, bariatric surgery, and lifestyle therapy in obese patients with MASLD, demonstrating semaglutide and surgery improve liver steatosis and fibrosis markers better than lifestyle changes alone, with semaglutide showing weight-independent benefits.
Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances
Posted inClinical Updates Diabetes & Endocrinology news

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances

COMBINE 4 demonstrated that once-weekly IcoSema (icodec+semaglutide) offers superior glycemic control, weight reduction, and reduced hypoglycemia versus daily insulin glargine U100 in insulin-naive type 2 diabetes patients, supported by complementary phase 3 studies on insulin icodec.
Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence
Posted inClinical Updates Diabetes & Endocrinology news

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence

This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesity, with a consistent safety profile.
Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
Posted inDiabetes & Endocrinology news

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with surgery but varying safety profiles.
Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial
Posted inDiabetes & Endocrinology news Psychiatry

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antipsychotics.
Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds
Posted inDiabetes & Endocrinology news Psychiatry

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds

A landmark Swedish cohort study of 95,490 patients reveals that semaglutide is associated with a 42% lower risk of worsening mental illness in people with depression and anxiety, while other GLP-1 receptor agonists show varied effects. The findings suggest potential dual therapeutic benefits for metabolic and mental health conditions.
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Synthesizing Evidence from Target Trial Emulations and Global Pharmacovigilance
Posted inClinical Updates Diabetes & Endocrinology news Ophthalmology

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Synthesizing Evidence from Target Trial Emulations and Global Pharmacovigilance

This review synthesizes recent evidence regarding the association between semaglutide initiation and nonarteritic anterior ischemic optic neuropathy (NAION), contrasting high-risk findings in real-world cohort studies with neutral findings in RCT meta-analyses and exploring potential mechanistic pathways.